TheEdgeResearch
Home / Stocks / NVS

Novartis AG (NVS)

NYSE Healthcare Drug Manufacturers - General
$153.81 ▼ -0.54%
Market Cap
$292.35B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.46
52-Wk Range
121.57-170.46
CEO
Vasant Narasimhan
Country
CH
Currency
USD

Novartis AG operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Basel, BS, CH. The stock last traded at $153.81, down 0.54% on the session, giving a market capitalisation of $292.35B. On trailing twelve-month figures it carries a trailing P/E of 23.21, a net margin of 23.1%. Its beta of 0.46 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
23.21
Price / Sales
5.31
Price / Book
6.99
EV / EBITDA
15.07
Gross margin
74.3%
Operating margin
29.9%
Net margin
23.1%
Return on equity
Debt / equity
1.18
Current ratio
0.86
Dividend yield
3.0%
Payout ratio
67.8%
Company profile
Exchange
New York Stock Exchange
Employees
75,267
IPO date
1996-11-07
Headquarters
Basel, BS, CH
About Novartis AG

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Comparable companies

Novartis AG is most often compared with the following Healthcare names:

ABBVAZNBAYRYBMYGILDGSKJNJLLYMRKPFE
More research on NVS
NVS technical analysis NVS TheEdge Score Compare against peers
Open full interactive analysis & DCF →